Source: Eur Respir J, 51 (2) 1702122; 10.1183/13993003.02122-2017
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
Jan Heyckendorf, Frank van Leth, Barbara Kalsdorf, Ioana D. Olaru, Gunar Günther, Helmut J.F. Salzer, Elena Terhalle, Thierry Rolling, Georg Glattki, Marius Müller, Maren Schuhmann, Korkut Avsar, Christoph Lange. Relapse-free cure from multidrug-resistant tuberculosis in Germany. Eur Respir J, 51 (2) 1702122; 10.1183/13993003.02122-2017

Member's Comments

No comment yet.

Related content which might interest you: Management of multidrug-resistant tuberculosis and patients in retreatment Source: Eur Respir J 2005; 25: 928-936 Year: 2005 Surgical treatment of multidrug-resistant tuberculosis (MDR TB) Source: Eur Respir J 2003; 22: Suppl. 45, 523s Year: 2003 Risk of mortality of extensively drug-resistant tuberculosis (XDR-TB) in Italy and Germany Source: Annual Congress 2007 - Multidrug-resistant tuberculosis and the emerging threat of extensively drug-resistant tuberculosis Year: 2007 Long-term treatment outcomes in multidrug-resistant tuberculosis (MDR-TB) Source: Annual Congress 2007 - Drug-resistant and multidrug-resistant tuberculosis Year: 2007 Recurrence after successful treatment among patients with multidrug-resistant tuberculosis Source: Annual Congress 2011 - Risk factors and treatment outcomes in multidrug- and extensively drug-resistant tuberculosis Year: 2011 Predictors of treatment outcome in multidrug-resistant tuberculosis in Portugal Source: Eur Respir J 2013; 42: 1747-1749 Year: 2013 Prevalence of MDR and XDR tuberculosis among patients with failure of re-treatment course Source: Annual Congress 2008 - The challenge of multidrug-resistant tuberculosis Year: 2008 Extensively drug-resistant tuberculosis (XDR-TB) and multidrug-resistant tuberculosis (MDR-TB): a retrospective comparative study Source: Annual Congress 2008 - Multidrug-resistant and the emerging threat of extensively drug-resistant tuberculosis Year: 2008 Multidrug-resistant tuberculosis (MDR-TB) Source: Breathe 2010; 6: 283 Year: 2010 Effect of fluoroquinolones on microbiologic outcome and survival in the treatment of multidrug-resistant tuberculosis Source: Eur Respir J 2006; 28: Suppl. 50, 380s Year: 2006 Comorbidome in multidrug-resistant tuberculosis patients Source: Virtual Congress 2020 – Tuberculosis and comorbidities Year: 2020 Multidrug-resistant tuberculosis (MDR-TB) and HIV co-infection in Romania Source: Annual Congress 2011 - Tuberculosis in immunocompromised hosts Year: 2011 Efficacy and safety of linezolid for the treatment of multidrug resistant tuberculosis (MDR-TB) and disease by non tuberculous mycobacteria (NTM) Source: Annual Congress 2011 - Treatment of tuberculosis and adverse drug reactions Year: 2011 Bedaquiline-based treatment regimen for multidrug-resistant tuberculosis Source: Eur Respir J, 49 (5) 1700742; 10.1183/13993003.00742-2017 Year: 2017 Treatment of TB Source: Eur Respir Mon 2012; 58: 154-166 Year: 2012 Determinants of multidrug-resistant tuberculosis (MDR-TB) in Belarus Source: Annual Congress 2012 - MDR- and XDR-TB: epidemiological and public health overview Year: 2012 Shorter regimens for multidrug-resistant tuberculosis should also be applicable in Europe Source: Eur Respir J, 49 (6) 1700228; 10.1183/13993003.00228-2017 Year: 2017 Shorter regimens for multidrug-resistant tuberculosis should also be applicable in Europe Source: Eur Respir J, 49 (6) 1700463; 10.1183/13993003.00463-2017 Year: 2017 Treatment outcomes for multidrug-resistant tuberculosis (MDR-TB) patients in Africa Source: Annual Congress 2011 - Multidrug-resistant tuberculosis Year: 2011 Analysis of multidrug-resistant tuberculosis Source: International Congress 2014 – Tuberculosis: from epidemiology to therapy 1 Year: 2014